ReFacto®

• The Newest Member of Our Hemophilia Franchise That Includes:

  • Factor VIII
  • BeneFIX®

• The First Recombinant Human Factor VIII Albumin-free Formulation

• Launched in Europe Mid-1999

• Approved in U.S. Spring 2000 for the Control and Prevention of Bleeding in Hemophilia Patients; Launched January 2001

• Manufacturing Capacity Expansion in St. Louis Expected in Early 2002

• ReFacto® AF to Begin Clinical Trials 2H2001

Providing a Higher Level of Safety for the Hemophilia Community

Previous slide

Next slide

Back to first slide

View graphic version